个人简历

学科方向\t 药物靶标的疾病分子机制研究

韩际宏教授, 南开大学生命科学院特聘教授, 博士生导师，973计划首席科学家。分别于1987年和1989年毕业于南开大学化学系和高分子研究所并取得学士和硕士学位。1995毕业于美国康乃尔大学医学院生物化学系，获博士学位。随后分别在美国西奈山医学院 (Mount Sinai School of Medicine), Hoffmann-La Roche Inc.制药公司, 康乃尔大学医学院血管生物学中心等完成博士后并工作数年。1999年和2004年分别被康乃尔大学医学院血管生物学中心聘为助理教授和副教授，2007年被聘为南开大学生命科学学院特聘教授。十余年来主要从事心血管生物学特别是动脉粥样硬化，巨噬细胞泡沫化分子生物学机制研究，结合胆固醇和脂代谢的研究寻找预防、减少动脉粥样硬化发病的机理和途径。在国际一流刊物上以主要作者身份发表五十多篇论文并多次在国际学术大会作报告，论文被引用近2000次。为多种国际学术刊物编辑或审阅稿件, 在该学术领域具有一定的影响力。

研究领域

心血管生物学""

近期论文

1. Liang Y, Han H, Liu L, Duan Y, Yang X, Ma C, Zhu Y, Han J, Li X, Chen Y. CD36 plays a critical role in proliferation, migration and tamoxifen-inhibited growth of ER-positive breast cancer cells. Oncogenesis 2018, in revision. 2. Ma J, Zhao D, Wang X, Ma C, Feng K, Zhang S, Chen Y, Zhu Y, Gao X, Zhao B, Wang Y, Qian K, Li X, Duan Y, Han J*, Yang X*. LongShengZhi capsule reduces established atherosclerotic lesions in apoE deficient mice. Journal of Cardiovascular Pharmacology 2018, accepted. 3. Liu L, Yang X, Duan Y, Zhang W, Ma C, Zhang X, Yang S, Li X, Yang J, Liang Y, Han H, Zhu Y, Han J*, Chen Y. Inhibition of vascular calcification—A new anti-atherogenic mechanism of DNA topoisomerase II inhibitors. Arteriosclerosis, Thrombosis and Vascular Biology, 2018;38:2382-2395. 4. Liu Y, Wei Z, Ma X, Chen Y, Yu M, Ma C, Li X, Cao Y, Gu J, Liu J, Han J, Yang X, Duan Y. Activation of liver X receptor plays a central role in antiviral actions of 25-hydroxycholesterol. Journal of Lipid Research, 2018, in revision. 5. Li Q, Chen Y, Zhao D, Wei Z, Zhang S, Chen Y, Wang Y, Qian K, Zhao B, Zhu Y, Gao X, Li X, Duan Y, Han J*, Yang X*. NaoXinTong capsule inhibits carrageenan-induced thrombosis in mice. Journal of Cardiovascular Pharmacology 2018;72:49-59. 6. Yang, S, Liu M, Chen Y, Ma C, Liu L, Zhao B, Wang Y, Li X, Zhu Y, Gao X, Kong D, Duan Y, Han J*,Yang X*. NaoXinTong Capsules inhibit the development of diabetic nephropathy in db/db mice. Scientific Reports 2018;8:9158. 7. Ma C, Zhang W, Liu Y, Liu L, Yang X, Feng K, Zhang X, Yang S, Sun L, Yu M, Yang J, Li X, Miao QR, Zhu Y, Han J*, Chen Y*, Duan Y*. Functional interplay between LXR and AMPKalpha reduces inhibits atherosclerosis tic lesions in apoE knockout mice-deficient mice--A new anti-atherogenic strategy. British Journal of Pharmacology 2018;175:1486-1503. 8. Owoicho Orgah J, Wang M, Yang X, Wang Z, Wang D, Zhang Q, Fan G, Han J, Qin G, Gao X, Zhu Y. Danhong Injection protects against hypertension-induced renal injury via down-regulation of myoglobin expression in spontaneously hypertensive rats. Kidney Blood Press Res. 2018;43:12-24. 9. Liu Y, Wei Z, Ma X, Yang X, Chen Y, Sun L, Yu M, Ma C, Gu J, Miao RQ, Hajjar DP, Han J*, Duan Y*. 25-Hydroxycholesterol induces its own production by activating cholesterol 25-hydroxylase expression in an LXR dependent mechanism. Journal of Lipid Research, 2018;59:439-451. 10. Zhang W, Yang X, Chen Y, Hu W, Liu L, Zhang X, Liu M, Sun L, Liu Y, Yu M, Li X, Li L, Zhu Y, Miao QR*, Han J*, Duan Y*. Activation of hepatic Nogo-B receptor expression--A new anti-liver steatosis mechanism of statins. BBA-Molecular Cell Biology of Lipid, 2018;1863:177-190. 11. Chen X, Feng Y, Shen X, Pan G, Fan G, Gao X, Han J, Zhu Y. Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro- and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis. Journal of Ethnopharmacology. 2018;211:358-365. 12. Lyu M, Yan C, Liu H, Chen X, Wang Y, Han J, Fan G, Zhu Y. Network pharmacology exploration reveals endothelial inflammation as a common target for coronary artery disease and stroke treatment by Danhong injection. Scientific Reports 2017;7:15427. 13. Yang X, Orgah J, Wang D, Fan G, Jingyang H, Han J, Qin G, Gao X, Zhu Y. Danhong injection reduces vascular remodeling and up-regulates the Kallikrein-kinin system in spontaneously hypertensive rats. Scientific Reports. 2017;7:4308. 14. Sun L, Yang X, Li Q, Zeng P, Liu Y, Liu L, Chen Y, Yu M, Ma C, Li X, Li Y, Zhang R, Zhu Y, Miao Q, Han J*, Duan Y*. Activation of adiponectin receptor regulates proprotein convertase subtilisin/kexin type 9 expression and inhibits lesions in apoE deficient mice. Arteriosclerosis, Thrombosis and Vascular Biology 2017;37:1290-1300. 15. Yu M, Liu Y, Duan Y, Chen Y, Han J, Sun L, Yang X. Inhibition of glutathione production by L-S,R-buthionine sulfoximine activates hepatic ascorbate synthesis--a unique anti-oxidative stress mechanism in mice. Biochemical and Biophysical Research Communications 2017;484:56-63. 16. Yang X, Li Y, Sun L, Liu Y, Ma C, Chen Y, Tan H, Li Q, Li X, Wang Y, Duan Y, Zhao B*, Han J*. NaoXinTong enhances atorvastatin-reduced atherosclerosis while antagonizing atorvastatin-induced hepatic inflammation. Journal of Cardiovascular Pharmacology 2017;69:55-64. 17. He S, Zhao T, Guo H, Meng Y, Qin G, Goukassian DA, Han J, Gao X, Zhu Y. Coordinated activation of VEGF/VEGFR-2 and PPARd pathways by a multi-component Chinese medicine DHI accelerated recovery from peripheral arterial disease in type 2 diabetic mice. PLoS One. 2016;11:e0167305. 18. Zhang K, Cai HX, Gao S, Yang GL, Deng HT, Xu GC, Han J, Zhang QZ, Li LY. TNFSF15 suppresses VEGF production in endothelial cells by stimulating miR-29b expression via activation of JNK-GATA3 signals. Oncotarget 2016;7:69436-69449. 19. Hu W, Zhang W, Chen Y, Rana U, Teng R, Duan Y, Liu Z, Zhao B, Foeckler J, Weiler H, Kallinger RE, Thomas MJ, Zhang K, Han J*, Miao QR*. Nogo-B receptor deficiency increases LXRalpha nuclear translocation and hepatic lipogenesis. Hepatology 2016;64:1559-1576. 20. Yu M, Jiang M, Chen Y, Zhang S, Zhang W, Yang X, Li X, Li Y, Duan S, Han J*, Duan Y*. 2016. Inhibition of macrophage CD36 expression and cellular oxLDL accumulation by tamoxifen--A PPARgamma dependent mechanism. The Journal of Biological Chemistry 2016;291:16977-89